IP Library Granted Patent US 10,669,245
Granted Patent B2
US 10,669,245 · App. 16/358,091 · Granted Jun 2, 2020

Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides dipeptidyl peptidase 1 inhibitors

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,669,245
App. No.
16/358,091
Granted
Jun 2, 2020
Kind
B2
Abstract

The present disclosure relates to certain (2S)—N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide compounds (including pharmaceutically acceptable salts thereof), that inhibit dipeptidyl peptidase 1 (DPP1) activity, to their utility in treating and/or preventing clinical conditions including respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), to their use in therapy, to pharmaceutical compositions containing them and to processes for preparing such compounds.

Claims (40)

1. A compound of formula (I)

wherein

R 1 is selected from

X is selected from O, S or CF 2 ;

Y is selected from O or S;

Q is selected from CH or N;

R 6 is selected from C 1-3 alkyl, wherein said C 1-3 alkyl is optionally substituted by 1, 2 or 3 F and optionally by one substituent selected from OH, OC 1 -3alkyl, N(C 1-3 alkyl) 2 , cyclopropyl, or tetrahydropyran;

R 7 is selected from hydrogen, F, Cl or CH 3 ;

or a pharmaceutically-acceptable salt thereof.

2. The compound of claim 1 , wherein

R 1 is

X is selected from O, S or CF 2 ;

Y is selected from O or S;

R 6 is selected from C 1-3 alkyl, wherein said C 1-3 alkyl is optionally substituted by 1, 2 or 3 F and optionally by one substituent selected from OH, OC 1 -3alkyl, N(C 1-3 alkyl) 2 , cyclopropyl, or tetrahydropyran;

R 7 is selected from hydrogen, F, Cl or CH 3 ;

or a pharmaceutically-acceptable salt thereof.

3. The compound of claim 2 , wherein

R 1 is

X is O;

R 6 is C 1-3 alkyl, wherein said C 1-3 alkyl is optionally substituted by 1, 2 or 3 F; and

R 7 is hydrogen;

or a pharmaceutically-acceptable salt thereof.

4. The compound of claim 3 , wherein

R 1 is

X is O;

R 6 is C 1-3 alkyl; and

R 7 is hydrogen;

or a pharmaceutically-acceptable salt thereof.

5. A pharmaceutical composition comprising a compound of claim 1 , and a pharmaceutically acceptable adjuvant, diluent or carrier.

6. A pharmaceutical composition comprising a compound of claim 2 , and a pharmaceutically acceptable adjuvant, diluent or carrier.

7. A pharmaceutical composition comprising a compound of claim 3 , and a pharmaceutically acceptable adjuvant, diluent or carrier.

8. A pharmaceutical composition comprising a compound of claim 4 , and a pharmaceutically acceptable adjuvant, diluent or carrier.

9. A method of treating an obstructive disease of the airway in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of the compound of claim 1 .

10. A method of treating an obstructive disease of the airway in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of the compound of claim 2 .

11. A method of treating an obstructive disease of the airway in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of the compound of claim 3 .

12. A method of treating an obstructive disease of the airway in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of the compound of claim 4 .

13. The method of claim 9 , wherein the administering comprises oral administration.

14. The method of claim 10 , wherein the administering comprises oral administration.

15. The method of claim 11 , wherein the administering comprises oral administration.

16. The method of claim 12 , wherein the administering comprises oral administration.

Assignments (7)
PATENT SECURITY AGREEMENT Recorded Oct 20, 2022
From: INSMED INCORPORATED
To: BIOPHARMA CREDIT PLC
Reel/Frame 061735/0875 →
SECOND LIEN PATENT SECURITY AGREEMENT Recorded Oct 19, 2022
From: INSMED INCORPORATED
To: ORBIMED ROYALTY & CREDIT OPPORTUNITIES IV, LP
Reel/Frame 061727/0039 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 26, 2019
From: BIOFOCUS DPI LTD
To: ASTRAZENECA AB
Reel/Frame 049283/0137 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 26, 2019
From: ASTRAZENECA UK LIMITED
To: ASTRAZENECA AB
Reel/Frame 049283/0150 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 26, 2019
From: CONNOLLY, STEPHEN; SWALLOW, STEVEN
To: ASTRAZENECA UK LIMITED
Reel/Frame 049283/0155 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 26, 2019
From: DOYLE, KEVIN; VAN DE POEL, AMANDA; JONES, GRAHAM; WATSON, DAVID; MACRITCHIE, JAQUELINE; PALMER, NICHOLAS
To: BIOFOCUS DPI LTD
Reel/Frame 049283/0129 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 26, 2019
From: PONTEN, JOHN FRITIOF; LONN, HANS ROLAND; AURELL, CARL-JOHAN; KARLSSON, STAFFAN PO
To: ASTRAZENECA AB
Reel/Frame 049283/0118 →